Retrospective analysis of nontraumatic subdural hematoma incidence and outcomes in Egyptian patients with end-stage renal disease on hemodialysis

Ahmed Fayed, Ayman Tarek, Mohamed I. Refaat, Sameh Abouzeid, Sohail Abdul Salim, Lajos Zsombó, Tibor Fülöp, Karim M. Soliman, and Mohamed A. Elmallawany

aNephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt; bNeurosurgery Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt; cNephrology Department, Theodor Bilharz Research Institute, Cairo, Egypt; dDepartment of Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, MS, USA; eFresenius Medical Care Hungary, Cegléd, Hungary; fDepartment of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA; gMedical Services, Ralph H. Johnson VA Medical Center, Charleston, SC, USA; hDepartment of Surgery, Transplant Nephrology, Medical University of South Carolina, Charleston, SC, USA

ABSTRACT

Background: The incidence of subdural hematoma (SDH) in chronic maintenance hemodialysis (CMH) patients may change over time, along with the evolving characteristics of the underlying populations.

Methods: We conducted a retrospective, single-center study at Cairo University hospitals, assessing the incidence, associated risk factors, and outcomes of nontraumatic SDH in CMH patients between January 2006 and January 2019.

Results: Out of 1217 CMH patients, nontraumatic SDH was diagnosed in 41 (3.37%) during the study, increasing with the enrollees’ age but stable over the observation period and translating into an annual incidence rate of 28 per 1000 patients per year. SDH patients were likely to use central venous catheters, reported pruritis and history of bone fractures, and had higher phosphorus, parathyroid hormone, and alkaline phosphatase values ($p < 0.001$); however, there was no association with atrial fibrillation or use of anticoagulants. In the SDH cohort ($n = 41$), six patients did not need surgical intervention and 13 patients died before becoming surgically fit for intervention; mortality correlated with ischemic heart disease ($p = 0.033$) and the presence of atrial fibrillation or chronic anticoagulation with warfarin ($p < 0.0001$ for both), among others. Twenty-two patients received surgical operations and of these 2 died postoperatively; overall patient mortality was 12/41 (29.27%) at 30 days and 15/41 (36.59%) at 1 year.

Conclusion: Our study demonstrated a striking enrichment for underlying comorbidities in those patients developing SDH and a high risk of immediate mortality. The benefit of chronic anticoagulation therapy should be carefully weighed against the risk of CNS bleed in MHD patients.

Introduction

In dialysis patients, cerebrovascular disease is common, often diagnosed late, and carries a substantial risk of morbidity and mortality. Among these, stroke is the third most common cause of death and cardiovascular disease is the leading cause of death; however, characteristics of cerebrovascular disease – including clinical subtypes and associated effects – are not well described in the literature [1].

Subdural hemorrhage (SDH) is generally more common in elderly patients and associated with a high rate of morbidity and mortality. Sozio et al. reported an annual incidence of chronic SDH is 1–5.3 cases per 100,000 populations [1]. More recent research reports even a higher incidence, perhaps due to improved imaging techniques [1,2]. SDH is also known to be a complication of long-term hemodialysis, and prevalence in chronic maintenance hemodialysis (CMH) patients doubled in recent years, likely attributable to the increased utilization of oral anticoagulant therapy [1,2]. Sood et al. also reported a 10-fold increased risk of developing SDH in CMH patients compared with that in the general population [3]. Moreover, one study in Japan reported that in patients on CMH, SDH accounts for as much as 8.6% of sudden deaths [4].

CONTACT Ahmed Fayed (dr.fayed@gmail.com) Nephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt
Because of multiple studies reporting a wide variance in incidence in CMH as well as insufficient data on risk factors and outcomes, we wished to explore these characteristics of SDH in our CMH population.

**Patient and methods**

This single-center, retrospective cohort study included data of all the adult subjects who were diagnosed with CMH at the Cairo University Hospital’s affiliated renal centers between 2006 and 2019. Kasr Al-Ainy University Hospital is a major hospital and tertiary referral center that serves patients from Cairo and all other governorates in Egypt. The University Hospitals’ three renal centers offer nephrological services to a large population with a total of more than 10,000 hemodialysis sessions per year.

All paper and electronic records related to admission, inpatient stay, laboratory tests, radiological investigations, and inpatient and outpatient dialysis data were analyzed. Baseline demographics and comorbidities such as heart failure, diabetes mellitus, essential hypertension, and atrial fibrillation with or without anticoagulant use were identified and confirmed during the follow-up period (Table 1). All cases of SDH were reviewed by the neurosurgical team at our center with regards to eligibility for surgical treatment; laboratory data were obtained at the initial presentation at an emergency room. In keeping with best surgical practice, guidelines for surgical evacuation in SDH were midline shift >5 mm or hematoma thickness >10 mm, regardless of the level of the Glasgow Coma Scale (GCS) [5].

During routine care, unfractionated heparin was used for all our patients on CMH and administered as a 500 IU bolus at the start of dialysis, followed by a maintenance dose of 500 IU every hour thereafter, plus an additional 50 IU for every 1 kg above ideal body weight in both patients’ bolus and maintenance doses. Dialysis session length varied from 4 to 6 h. Dialysis adequacy was measured monthly by single-pool Kt/V (spKt/V).

### Table 1. Demographic and laboratory data of our patients received maintenance HD and patients experienced nontraumatic subdural hematoma (SDH).

| Variables | Without non-traumatic SDH [1176] | With non-traumatic SDH [41] | p-Value |
|-----------|----------------------------------|-----------------------------|---------|
| Age (Years) (Mean ± SD) | 50.3 ± 13.8 | 56.3 ± 14.3 | 0.0064 |
| Smoking (Number (%)) | 339 (28.8) | 6 (14.6) | 0.0474 |
| Female (Number (%)) | 595 (50.6) | 18 (44) | 0.4062 |
| Male (Number (%)) | 581 (49.4) | 23 (56) | 0.4031 |
| Major co-morbidity (Number (%)) | | | |
| 1. Diabetes mellitus | 767 (65.2) | 28 (68.3) | 0.6820 |
| 2. Systemic hypertension | 937 (79.7) | 32 (78.1) | 0.8026 |
| 3. Ischemic Heart Disease | 474 (40.3) | 14 (34.2) | 0.4336 |
| 4. Malignancy | 56 (4.8) | 0 (0) | 0.1510 |
| 5. Fractures | 28 (2.4) | 5 (12.2) | 0.0002 |
| 6. Atrial fibrillation | 234 (19.9) | 10 (24.4) | 0.4795 |
| 7. Thrombosis | 14 (1.2) | 0 (0) | 0.4807 |
| 8. Use of oral anticoagulants (warfarin) | 248 (21.1) | 10 (24.4) | 0.6115 |
| 9. Use of aspirin/clopidogrel | 937 (79.7) | 32 (78.1) | 0.8026 |
| 10. Hepatitis C virus | 345 (28.3) | 5 (12.2) | 0.0237 |
| 11. Hepatitis B virus | 3 (0.3) | 2 (2.8) | 0.0110 |
| 12. Urine volume <400 ml | 980 (83.3) | 39 (95.2) | 0.0427 |
| 13. Urine volume >400 ml | 196 (16.7) | 2 (2.8) | 0.0177 |

**Dialysis vintage, in years (Mean ± SD)**

- Three sessions weekly each session 4 h
- 3.4 ± 0.2
- 2.8 ± 2.3

**Vascular Access (Number (%))**

- Arterio-Venous Fistula | 1049 (89.2) | 26 (63.4) | <0.0001 |
- Graft | 77 (6.5) | 1 (2.4) | 0.2906 |
- Tunneled Dialysis Catheters | 50 (4.3) | 14 (34.2) | <0.0001 |

**Laboratory data (Mean ± SD)**

| Hemoglobin conc. (12-15.5 g/dL) | 9.9 ± 1.8 | 11 ± 2.4 | 0.0002 |
| Platelet count (150–450 × 10^9/ml) | 260 ± 70.1 | 173 ± 75 | <0.0001 |
| Ferritin (20–250 ng/ml) | 326 ± 60 | 162 ± 21.7 | <0.0001 |
| PT (11–13.5 seconds) | 13 ± 0.9 | 11.4 ± 0.7 | <0.0001 |
| APTT (30–40 seconds) | 32.2 ± 2.9 | 32.5 ± 3.2 | 0.5166 |
| Fibrinogen (2–4 g/L) | 4.4 ± 0.5 | 4.22 ± 0.74 | 0.0264 |
| Serum albumin (3.4–5.4 g/L) | 3.2 ± 0.4 | 3.3 ± 0.5 | 0.1192 |
| Corrected calcium (8.6–10.2 mg/dl) | 8.3 ± 0.9 | 8.5 ± 0.7 | 0.1594 |
| Phosphorous (3–4.5 mg/dl) | 5 ± 0.8 | 6 ± 2 | <0.0001 |
| Serum parathormone (10–55 pg/mL) | 355.5 ± 74.2 | 420.2 ± 93.1 | <0.0001 |
| Alkaline phosphatase (44–147 U/L) | 137.4 ± 7.5 | 156.9 ± 79.7 | <0.0001 |
| Single pool Kt/V (1.2) | 5.4 ± 1.6 | 6.8 ± 2.7 | <0.0001 |

PT: prothrombin time; APTT; activated partial thromboplastin time. *p < 0.05 are significantly different.
using the Daugirdas method. Dialysis prescription was tailored to achieve an spKt/V of \( \geq 1.6 \).

All processes carried out in this study involving human subjects followed the ethical principles of the institutional and/or national research committee, the Declaration of Helsinki of 1964, and the latter’s corresponding amendments or similar ethical criteria. All individual participants participating in the study received informed consent. The local ethical committee of the Department of Internal Medicine, School of Medicine, Cairo University, approved this work in December 2019.

### Statistical analysis

Precoded data were entered on the computer using Microsoft Excel 2010 for Windows. Data were then transferred to the Statistical Package of Social Science Software program (SPSS-25) to be statistically analyzed. Continuous variables were expressed as mean ± standard deviation. Frequency and percentage were done for qualitative variables. Comparisons between quantitative variables were done using the nonparametric Kruskal–Wallis and Mann–Whitney tests [6]. For comparing categorical data, a chi-squared \( (\chi^2) \) test was performed. When the expected frequency was less than 5, Fisher’s exact test was used instead [7]. Correlations between quantitative variables were done using the Spearman correlation coefficient [8]. A \( p \)-value of less than 0.05 was considered statistically significant.

### Results

Demographic and laboratory data of our patients are shown in Tables 1 and 2. Systemic hypertension was the most common cause of ESRD as well as the major co-morbidity. Non-traumatic SDH in CMH patients was found to be 0.4% prevalent at our center, with an annual incidence of 189 per 100,000 patients, compared to the prevalence previously recorded in nonhemodialysis patients (1–5.3 cases per 100,000 populations). Out of 1217 CMH patients, nontraumatic SDH developed in 41 (3.37%) during the study period, translating to an annual incidence rate of 28 per 1000 patients per year. SDH incidence was associated with increased age of the patient (the age of CMH patients

Table 2. Comparison of survivors and non survivors in patients experienced nontraumatic subdural hematoma (SDH).

| Variables                        | Survivors in nontraumatic SDH (Mean ± SD) | Nonsurvivors in nontraumatic SDH (Mean ± SD) | \( p \)-Value |
|----------------------------------|------------------------------------------|---------------------------------------------|--------------|
| Age (Years) (Mean ± SD)          | 55.7 ± 1.9                               | 71.5 ± 1.4                                  | <0.0001      |
| Smoking (Number (%))             | 3 (28.4)                                 | 3 (14.6)                                    | 0.4728       |
| Female (Number (%))              | 11 (50.4)                                | 7 (44)                                      | 0.0699       |
| Male (Number (%))                | 15 (49.6)                                | 8 (56)                                      | 0.7928       |
| Major co-morbidity (Number (%))  |                                          |                                             |              |
| 1. Diabetes mellitus             | 18 (69.2)                                | 10 (66.7)                                   | 0.8692       |
| 2. Systemic hypertension         | 19 (73.1)                                | 13 (86.7)                                   | 0.3234       |
| 3. Ischemic Heart Disease        | 12 (46.2)                                | 2 (13.3)                                    | 0.0332       |
| 4. History of prior fractures    | 5 (19.2)                                 | 0 (0)                                       | 0.0729       |
| 5. Atrial fibrillation           | 1 (3.8)                                  | 9 (60)                                      | 0.0001       |
| 6. Use of oral anticoagulants (warfarin) | 1 (3.8)                                           | 9 (60)                                      | 0.0001       |
| 7. Use of aspirin/clopidogrel    | 22 (84.6)                                | 10 (66.7)                                   | 0.19001      |
| 8. Hepatitis C virus             | 4 (15.4)                                 | 1 (6.7)                                     | 0.4239       |
| 9. Hepatitis B virus             | 2 (7.7)                                  | 0 (0)                                       | 0.29909      |
| 10. Urine volume <400 ml         | 24 (92.3)                                | 15 (100)                                    | 0.02822      |
| 11. Urine volume >400 ml         | 2 (7.7)                                  | 0 (0)                                       | 0.29909      |
| Subdural thickness (Number (%))  |                                          |                                             |              |
| Subdural thickness >20 mm        | 15 (57.7)                                | 13 (86.7)                                   | 0.0576       |
| Subdural thickness >10 mm        | 11 (42.3)                                | 2 (13.3)                                    | 0.0576       |
| Laboratory data (Mean ± SD)      |                                          |                                             |              |
| Hemoglobin conc. (12–15.5 g/dL)  | 12.1 ± 1.3                               | 9.5 ± 0.7                                   | <0.0001      |
| Platelet count (150–450 x 10^9/ml) | 1813 ± 9.2                               | 144 ± 6.8                                   | <0.0001      |
| Ferritin (20–250ng/ml)           | 201.3 ± 35.8                             | 314.5 ± 14.1                                | <0.0001      |
| PT (11–13.5 seconds)             | 11.5 ± 0.3                               | 11.6 ± 0.1                                  | 0.01701      |
| APTT (30–40 seconds)             | 32.3 ± 1.7                               | 32.8 ± 0.1                                  | 0.30276      |
| Fibrinogen (2–4 g/L)             | 4.3 ± 0.1                                | 4.4 ± 0.1                                   | 0.00076      |
| Serum albumin (3.4–5.4 g/L)      | 3.5 ± 0.2                                | 2.9 ± 0.1                                   | <0.0001      |
| Corrected calcium (8.6–10.2mg/dl) | 8.6 ± 0.2                               | 8.5 ± 0.2                                   | 0.7537       |
| Phosphorus (3–4.5 mg/dl)         | 6.1 ± 0.5                                | 6.4 ± 0.3                                   | 0.01812      |
| Alkaline phosphatase (44–147U/L) | 162.3 ± 5.9                              | 163.2 ± 4.7                                 | 0.6049       |
| Serum parathormone (10–55 pg/mL) | 427.1 ± 21.6                             | 419.3 ± 18.2                                | 0.2475       |
| Uric Acid (2.4–6mg/dl)           | 6.9 ± 0.3                                | 6.9 ± 0.3                                   | 0.9057       |
| Single pool Kt/V (1.2)           | 1.3 ± 0.1                                | 1.3 ± 0.1                                   | 0.6952       |

PT: prothrombin time; APTT; activated partial thromboplastin time. *\( p \)-value of less than 0.05 are significantly different.
was $50.7 \pm 14.2$ whereas the age of nontraumatic SDH was $50.3 \pm 13.8$, $p$-value 0.0064). We found a good linear relationship between the cumulative incidence of SDH and time (year) (Figure 1).

Occurrence of nontraumatic SDH in CMH patients was statistically more likely with shorter dialysis vintage ($p < 0.001$), use of central venous catheters ($p < 0.001$), and reported history of past bone fractures ($p = 0.0001$) but not with atrial fibrillation or use of anticoagulants (Table 1). Moreover, those with SDH had significantly lower hemoglobin and lower ferritin values ($p < 0.001$) but higher phosphorus, parathyroid hormone, and alkaline phosphatase (Table 1). Among those with SDH, death was more likely observed in those with underlying ischemic heart disease ($p = 0.033$) and the presence of atrial fibrillation and chronic anticoagulation ($p < 0.001$) (Table 2).

Of the 41 patients, six patients had a small hematoma that was not large enough for surgical intervention; 13 patients died before being surgically fit for intervention; and 22 patients received surgery, of these 2 died postoperatively (Table 3). SDH thickness $>20$ mm was found in 28/41 (68.29%) cases, whereas 13/41 (31.7%) cases had a significant ($>10$ mm) associated midline shift. Patient mortality was 12/41 (29.27%) at 30 days and 15/41 (36.59%) at 1 year. At 1 year, 13/15 (70.73%) of patient deaths occurred in patients deemed not eligible for surgical intervention with an SDH thickness $>20$ mm and/or midline shift $>10$ mm. All these patients died as a direct result of SDH. Of the 22 cases who underwent surgery, 15 (68%) had acute SDH, four (18%) had subacute SDH, and three (14%) had chronic SDH. The subacute and chronic cases (7 patients) underwent burr hole evacuation whereas the acute cases (15 patients) underwent a decompressive flap and duroplasty. Among these, two died and 13 survived (Table 3).

Discussion

This retrospective observational study reaffirmed the high incidence and mortality of SDH in CMH patients, particularly in the elderly. Moreover, our study also demonstrated a striking enrichment of underlying comorbidities in those patients who developed SDH. Overall mortality results in our population are comparable to studies on CMH patients from the United States reporting 29.27% and 4.88% mortality rates at 30 days and after 30 days, respectively [9]. In concordance with our results, Wang et al. reported a 35.2% 30-day mortality rate in CMH patients who develop SDH [10].

The higher incidence of SDH in CMH patients can be explained by several factors. The risk of bleeding is increased by the use of heparin with dialysis, as well as by concurrent administration of warfarin or antiplatelet for cerebrovascular diseases, cardiovascular diseases, or atrial fibrillation. Increased risk of bleeding can also be attributed to the uremic state itself. The etiology for increased bleeding tendency in the uremia is not completely understood but impaired platelet function is one of the main determinants of uremic bleeding [11]. This impairment is largely due to incompletely defined inhibitors of platelet function in the plasma of patients with markedly reduced kidney function. Abnormal
platelet–endothelial interaction and anemia also play a role [5, 12].

Further, Rossier et al. found that elderly dialysis patients are at higher risk compared with the general population or compared with young CMH patients [13]. Possibly explanations for this propensity may include protein malnutrition, vitamin D deficiency, mineral bone diseases, cognitive impairment, and post-dialysis hypotension, which may all increase susceptibility for falls in CMH patients [14]. In patients with ESRD, brain atrophy is common, affects as much as 77.5% of those with CMH, and will increase the length of the bridging veins that are prone to tearing [15]. Hemodialysis has been associated with higher fluctuations in intracranial pressure, alteration in cerebral blood flow, and decreased pressure in subdural space during the intradialytic period [16]. Cortical atrophy may be linked to repeated hypotensive episodes in CMH patients [17,18].

In concordance with other studies, we demonstrated an increased risk of death in nontraumatic SDH in CMH patients with ischemic heart disease, atrial fibrillation, and the use of oral anticoagulants (\(p\)-value < 0.001) [3,19]. The presence of an anticoagulated state will increase the length of time needed for reversal of anticoagulant effect during preoperative preparation and allows the increase in the size of hematoma during this time interval. It is also possible that the presence of oral vitamin-K antagonist may contribute to tissue fragility beyond the simple anticoagulation effect, via interfering with matrix Gla protein synthesis [20].

Factors that have been found to increase the vulnerability to falls for CMH patients include advanced age, comorbidities, cognitive impairment, psychotropic drug use, blood pressure drug use, malnutrition, post-dialysis hypotension, renal bone diseases, and vitamin D deficiency. Cognitive dysfunction can result from uremia itself and neuropsychiatric adverse effects from widely used drugs are likely to occur in patients with end-stage renal disease (ESRD), including those on dialysis [17]. Falls even without fractures have also been related to an increased risk of traumatic SDH in CMH patients [2]. These findings were aligned with our results, which demonstrated the statistically higher incidence of non-traumatic SDH in CMH patients with diabetes mellitus, systemic hypertension, ischemic heart disease, atrial fibrillation, the use of oral anticoagulants, the presence of fractures, and dysfunction in bone minerals such as low serum albumin, low serum calcium, high alkaline phosphatase, high serum parathormone, elevated uric acid, and high spKt/V. We found a statistically higher incidence of nontraumatic SDH in CMH patients with hepatitis C virus and hepatitis B virus infections. This seemed to be linked to the fact that these subjects are more vulnerable to more severe arterial calcification [21].

Subacute and chronic subdural hematomas were handled by wide burr holes fashioned to reach the entire extensions of the hematoma due to its liquefied blood content due to enzymatic fibrinolysis. The burr hole should be wide enough (more than 2.5 cm in diameter) to allow continuous free drainage and prevent recurrence with careful dura coagulation to shrink its edges back to full width [22]. All of the above considerations help in successful drainage and the prevention of recurrence [22]. More commonly, acute subdural hematomas are associated with more impact damage and a rapid increase in intracranial pressure, leading to efficient drainage and preventing recurrence [22]. Attention is required for the increased risk (up to sevenfold in males and 26-fold in females) of acute subdural hematoma in patients receiving anticoagulants [23]. Timing is crucial, as previous studies have illustrated the ‘four-hour rules’ in which mortality rate is 30% for posttraumatic acute SDH in cases operated within four hours compared with 90% if surgery was postponed [24]. This explains that preoperative cases

---

### Table 3. Indications, interventions, surgical techniques and outcomes of survivors and nonsurvivors in patients experienced nontraumatic subdural hematoma (SDH).

| Variables | Survivors in nontraumatic SDH (Number (%)) | Nonsurvivors in nontraumatic SDH (Number (%)) | \(p\)-Value |
|-----------|------------------------------------------|---------------------------------------------|-------------|
| Surgical intervention was not done in 19 cases (46.3%) | 6 (23.1) | 0 (0) | 0.0466 |
| The hematoma was not sizable enough | 0 (0) | 13 (86.7) | <0.0001 |
| Surgical intervention was done in 22 cases (53.4%) | 13 (50) | 2 (13.3) | 0.0203 |
| Acute subdural hematoma | 7 (26.9) | 0 (0) | 0.0294 |
| Sub-acute and chronic SDH | 7 (26.9) | 0 (0) | 0.0294 |
| The technique of surgical intervention | 13 (50) | 2 (13.3) | 0.0203 |
| Burr-hole evacuation | 12 (80) | 3 (20) | 0.0012 |

*\(p\) < 0.05 are significantly different.
died (13 cases) largely from coagulopathy because they were not prepared for surgical intervention. In conjunction with duroplasty, a decompressive craniectomy flap was performed in our cohort with at least 12 cm in diameter. Both requirements are mandatory for achieving a decrease in intracranial pressure below 20 mmHg postoperatively. Kurland et al. demonstrated a survival outcome of 86.7% in SDH cases who underwent decompressive flap and duroplasty [25]. The authors concluded that decompressive craniectomy is an efficient lifesaving way to regulate elevated intracranial pressure, which accounts for the drastic increase in the use of this procedure.

The main strength of our study is its focus on CMH patients from a contemporary cohort who developed SDH, reflecting the current co-morbid burden of MHD patients and neurosurgical practice both. This study increases the understanding of outcomes in CMH patients developing SDH and highlights the necessity of increasing efforts to conduct prospective randomized controlled trials in the field. Our study is also not without limitations. Observational studies are more prone to bias, and a retrospective nature has limited our ability to capture baseline information, including lifestyle, smoking habits, and body mass index of patients. The definitive cause of SDH could not be confirmed, possibly because of reporting bias.

Conclusion

Our study demonstrated a striking enrichment for underlying comorbidities in those patients developing SDH and a high risk of immediate mortality. The benefit of chronic anticoagulation therapy should be carefully weighed against the risk of CNS bleed in MHD patients.

Compliance with Ethical Standards

This material has not been published previously, in whole or part, and is not under consideration for publication elsewhere. This paper has no tables or figures that would require permission to reprint. The authors have no conflict of interest to declare. All authors had participated in the preparation of this manuscript, fulfilled the criteria for authorship, and have approved the paper in the current format. The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in the prior approval by the institution’s human research committee. This study was not supported by any grant.

Disclosure statement

Drs. Fülöp, Soliman and Zsom are serving on the Editorial Board of the journal Renal Failure, including Dr. Fülöp is the Editor-in-Chief and Dr Zsom is an Associate Editor for the journal. Dr. Fülöp is a current employee of the United States Department of Veteran Health Administrations. However, the views and opinions expressed herewith do not reflect the official views or opinion or endorsed by the United States Veteran Health Administrations.

Funding

The author(s) reported there is no funding associated with the work featured in this article.

ORCID

Ahmed Fayed http://orcid.org/0000-0002-6041-4016
Sohail Abdul Salim http://orcid.org/0000-0001-7304-6307

References

[1] Sozio SM, Armstrong PA, Coresh J, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis. 2009;54(3):468–477.
[2] Wang IK, Lin CL, Wu YY, et al. Subdural hematoma in patients with end-stage renal disease receiving hemodialysis. Eur J Neurol. 2014;21(6):894–900.
[3] Sood P, Sinson GP, Cohen EP. Subdural hematomas in chronic dialysis patients: significant and increasing. Clin J Am Soc Nephrol. 2007;2(5):956–959.
[4] Toi H, Kinoshita K, Hirai S, et al. Present epidemiology of chronic subdural hematoma in Japan: analysis of 63,358 cases recorded in a national administrative database. J Neurosurg. 2018;128(1):222–228.
[5] Zwaginga JJ, Ijsselelijing MJ, de Groot PG, et al. Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. Arterioscler Thromb. 1991;11(3):733–744.
[6] Chan YH. Biostatistics 102: quantitative data–parametric and non-parametric tests. Singapore Med J. 2003; 44(8):391–396.
[7] Chan YH. Biostatistics 103: qualitative data - tests of independence. Singapore Med J. 2003;44(10):498–503.
[8] Chan YH. Biostatistics 104: correlational analysis. Singapore Med J. 2003;44(12):614–619.
[9] Abdel-Rahman EM, Turgut F, Turkmen K, et al. Falls in elderly hemodialysis patients. QJM. 2011;104(10):829–838.
[10] Łukaszewicz AM, Grant RA, Basques BA, et al. Patient factors associated with 30-day morbidity, mortality, and length of stay after surgery for subdural hematoma: a study of the American college of surgeons national surgical quality improvement program. JNS. 2016;124(3):760–766.
[11] Wang IK, Cheng YK, Lin CL, et al. Comparison of subdural hematoma risk between hemodialysis and peritoneal dialysis patients with ESRD. Clin J Am Soc Nephrol. 2015;10(6):994–1001.
[12] Lisowska-Myjak B. Uremic toxins and their effects on multiple organ systems. Nephron Clin Pract. 2014; 128(3-4):303–311.
[13] Linthorst GE, Avis HJ, Levi M. Uremic thrombocytopenia is not about urea. J Am Soc Nephrol. 2010;21(5):753–755.

[14] Rossier A, Pruijm M, Hannane D, et al. Incidence, complications and risk factors for severe falls in patients on maintenance haemodialysis. Nephrol Dial Transplant. 2012;27(1):352–357.

[15] Yang AI, Balser DS, Mikheev A, et al. Cerebral atrophy is associated with development of chronic subdural haematoma. Brain Inj. 2012;26(13-14):1731–1736.

[16] Fang D, Chabrier-Rosello JO, McMahon BA, et al. Achieving osmotic stability in the context of critical illness and acute kidney injury during continuous renal replacement therapy. Asaio J. 2020;66(7):e90–e93.

[17] Ali H, Soliman K, Mohamed MM, et al. The effects of dialysis modality choice on cognitive functions in patients with end-stage renal failure: a systematic review and meta-analysis. Int Urol Nephrol. 2021;53(1):155–163.

[18] Lund A, Damholt MB, Strange DG, et al. Increased intracranial pressure during hemodialysis in a patient with anoxic brain injury. Case Rep Crit Care. 2017;2017:5378928.

[19] Kudo H, Kuwamura K, Izawa I, et al. Chronic subdural hematoma in elderly people: present status on awaji island and epidemiological prospect. Neurol Med Chir (Tokyo). 1992;32(4):207–209.

[20] Mizuiri S, Nishizawa Y, Yamashita K, et al. Relationship of matrix gla protein and vitamin K with vascular calcification in hemodialysis patients. Renal Failure. 2019;41(1):770–777.

[21] Fayed A, Soliman A, El Mahdy H, et al. Impact of hepatitis virus infection on arterial calcification among incident hemodialysis patients. Nefrologia. 2020;40(3):336–344.

[22] Abdelfatah MAR. Recurrence rate of chronic subdural hematoma after evacuating it by two large burr holes, irrigation, and subgaleal Low-Pressure suction drainage. Asian J Neurosurg. 2019;14(3):725–729.

[23] Wintzen AR, Tijssen JGP. Subdural hematoma and oral anticoagulant therapy. Arch Neurol. 1982;39(2):69–72.

[24] Seelig JM, Becker DP, Miller JD, et al. Traumatic acute subdural hematoma: major mortality reduction in comatose patients treated within four hours. N Engl J Med. 1981;304(25):1511–1518.

[25] Kurland DB, Khaladj-Ghom A, Stokum JA, et al. Complications associated with decompressive craniectomy: a systematic review. Neurocrit Care. 2015;23(2):292–304.